SOUTHERN JOURNAL OF SCIENCES

Background: The American food regulatory landscape has historically been influenced by industry interests, resulting in the widespread use of petroleum-derived synthetic food dyes banned in European countries. Chronic disease rates in American children have increased from 3% in the 1960s to approximately 60% currently, with annual healthcare costs reaching $1 trillion. The appointment of Robert F. Kennedy Jr. as Secretary of Health and Human Services marks a paradigmatic shift toward transparency and industry accountability in food safety regulation. Aim: This forum analysis examines Kennedy Jr.'s revolutionary approach to food safety regulation, particularly his confrontational stance against petroleum-based food additives exemplified by his statement, "if they want to eat petroleum, they should add it themselves at home" and evaluates the broader implications for American public health policy and global regulatory standards. Methods: Critical analysis of Kennedy Jr.'s public policy statements, examination of epidemiological data trends, and evaluation of proposed regulatory frameworks through content analysis of official speeches and policy declarations from the Department of Health and Human Services. Results: Kennedy Jr.'s administration targets the systematic elimination of synthetic food dyes through industry partnerships, scientific transparency initiatives, and restoration of rigorous research standards. His confrontational rhetorical approach, compared to Mike Tyson's boxing style, has generated unprecedented industry cooperation with food companies "calling almost daily" seeking compliance guidance. The strategy combines voluntary industry agreements with open-source information databases and enhanced FOIA access. Discussion: This confrontational rhetoric represents unprecedented directness in health policy communication, challenging decades of established regulatory practices. The approach prioritizes scientific transparency over diplomatic language, generating both media attention and voluntary industry engagement that traditional regulatory pressure failed to achieve. Conclusions: Kennedy Jr.'s revolutionary stance may establish new global standards for food additive oversight, prioritizing public health over commercial interests through evidence-based policymaking and industry accountability measures. This paradigm shift from reactive to preventive regulatory models could influence international food safety governance and restore American leadership in global health policy.

Background: The Epstein-Barr virus (EBV) has recently been identified in human breast cancer globally, potentially contributing to the initiation and progression of this malignancy, as well as gastric cancer, nasopharyngeal carcinoma, and bladder cancer. It has been newly associated with breast cancer. Globally, breast cancer affects more women than any other type of cancer. In Iraq, the prevalence of breast cancer is comparable. Aims: The study examined Iraqi women diagnosed with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) to detect Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1) and encoded RNA (EBER). Methods: A total of 50 formalin-fixed paraffin-embedded tissues from invasive ductal carcinoma (IDC) (92%) and invasive lobular carcinoma (ILC) (8%) biopsy samples constituted the case group, while 30 formalin-fixed paraffin-embedded tissues from non-cancerous breast tissue served as the control group. The presence of Epstein-Barr virus protein (EBER) in breast tissue was assessed using immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) methods. Results: EBER RNA signals were found in 31 (62%). EBER RNA signals were seen in 3 (10%) control group participants. Significant differences (P<0.04) were seen in EBV EBER RNA positive signals among study groups. Immunohistochemistry showed nuclear brown staining in 34 (68%) breast cancer patients. Control group: 3 (10%). Discussion: The research identified a statistically significant correlation between EBV positivity and breast cancer among Iraqi women, especially concerning invasive ductal carcinoma. The results corroborate previous reports of elevated EBV levels in malignant breast tissues relative to controls. Although detection approaches such as CISH and IHC provide complementary insights, additional studies are needed. Conclusions: The study concludes that EBNA-1 and EBV EBER RNA were overexpressed in our population group.

Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous hematological malignancy predominantly affecting individuals under 20 years of age. Traditional chemotherapy, such as clofarabine, has shown efficacy; however, novel immunotherapeutic strategies like tisagenlecleucel (Kymriah®) have significantly altered the treatment paradigm. Aim: This study aimed to perform a comparative analysis of tisagenlecleucel, a CAR-T cell therapy, and clofarabine, a second-generation purine nucleoside analog, evaluating their mechanisms of action, therapeutic benefits, limitations, and clinical applicability across diverse patient populations. Methods: A systematic comparative evaluation was conducted, encompassing pharmacological characteristics, mechanisms of action, treatment protocols, efficacy, safety profiles, and clinical indications of both agents. The analysis considered pharmacokinetic and pharmacodynamic data and included patient demographic variables. Results: Tisagenlecleucel demonstrated high efficacy in refractory B-cell ALL, with durable responses and a blood half-life of 128 days, but with notable immune-related adverse effects such as cytokine release syndrome. Clofarabine, effective across a broader patient population, acts via multiple antitumor mechanisms but carries significant toxicity risks, including infection and sepsis. Discussion: The therapies present distinct clinical profiles: tisagenlecleucel offers targeted immunotherapy with high specificity but requires specialized infrastructure and management of immune toxicities. Clofarabine is more widely accessible and applicable, but is associated with conventional chemotherapy-related side effects. Treatment accessibility and cost differ markedly between the two. Conclusions: Therapy selection should be personalized based on patient-specific factors and institutional resources. Tisagenlecleucel is ideal for pediatric and young adult patients with relapsed/refractory B-cell ALL in CAR-T-capable centers, while clofarabine remains a viable option for broader ALL populations, particularly when genetic therapies are not feasible. Further research is needed to optimize therapeutic strategies and improve access to advanced treatments.